Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis
Quebec Innovative Materials:Advancing Canadian and American Natural Hydrogen for the Next Energy Cycle